102 Cases of Acute Upper Respiratory Infection Treated with Lianhuaqingwen Capsule

Objective To evaluate the efficacy and safety of lianhuaqingwen capsule for treating acute upper respiratory tract infection. Methods The clinical randomized-controlled-trails were conducted.VitC yinqiao tablets was used as control.A total of 206 subjects with acute upper respiratory tract infection were enrolled in our study,in which 102 patients randomly assigned in the treatment group were orally given lianhuaqingwen capsule(4 capsules,tid) for 3 d,and the other 104 patients were orally administered with VitC yinqiao tablets(2 pills,tid) for 3 d. Results The clinical efficacy rates were 91.2% and 73.1% in lianhuaqingwen capsule group,and VitC yinqiao tablets group,respectively.Compared with control group,lianhuaqingwen capsule was more effective for improving main symptoms including fever,chill,headache and myalgia,with the therapeutic rates for whjch were 90.2%,85.4%,89.5%,91.0%,respectively.No significant difference on incidence of side effects in both groups was found(P0.05). Conclusion The results suggest that lianhuaqingwen capsule is an effective and safe agent for treating acute upper respiratory tract infection,and is superior to VitC yinqiao tablets.